Skip to main content

Advertisement

Fig. 1 | BMC Neurology

Fig. 1

From: Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study

Fig. 1

Kaplan-Meier survival estimates pertaining to probabilities of being free of the occurrence of any relapse (a) between during MMF treatment (on-MMF, dashed line) and before MMF treatment initiation (pre-MMF, black line) in NMOSD patients (Log-rank test, p < 0.001). The relapse-free rates after 1 year and 2 years therapy with MMF were 72% and 58%, respectively. Those values were much higher than 30% and 14% before initiation of MMF therapy. (b) with different dose of MMF therapy. After 20 months of MMF therapy, approximately 68% and 42% of NMOSD patients in the high-dose and moderate-dose groups would remain relapse-free, respectively (Log-Rank test, p = 0.019). However, only 9% of the patients receiving low-dose MMF would remain relapse-free, significant lower than the moderate or high-dose groups (Log-Rank test p = 0.031, p < 0.0001)

Back to article page